Biotechnology: Biological Products (No Diagnostic Substances) Stocks
133 biotechnology: biological products (no diagnostic substances) stocks ranked by market capitalization. Updated October 11, 2026.
MetaCap tracks 133 US-listed companies in the Biotechnology: Biological Products (No Diagnostic Substances) industry, part of the broader Health Care sector, worth a combined $883.84B. The largest biotechnology: biological products (no diagnostic substances) stocks are Amgen (AMGN, $224.3B), Gilead Sciences (GILD, $187.4B) and Moderna (MRNA, $89.8B). The biggest company alone accounts for about 25% of the industry's total market value, and the median member is worth $4.1B. On the latest trading day, 48 of 50 biotechnology: biological products (no diagnostic substances) stocks shown were higher, with an average move of +3.69%; Novavax (NVAX) led with a 15.80% gain.
Summary generated from market data by MetaCap's automated system. Methodology
Largest biotechnology: biological products (no diagnostic substances) stocks by market cap
| # | Symbol | Company | Price | % Change | Volume | Market Cap |
|---|---|---|---|---|---|---|
| 1 | AMGN | Amgen Inc. | 414.87 | +1.82% | 2.55M | $224.29B |
| 2 | GILD | Gilead Sciences Inc. | 151.17 | +2.77% | 5.80M | $187.44B |
| 3 | MRNA | Moderna Inc. | 225.00 | +14.21% | 28.95M | $89.83B |
| 4 | ARGX | argenx SE ADR | 825.03 | +0.78% | 512.25K | $51.88B |
| 5 | RVMD | Revolution Medicines Inc. | 189.76 | +0.87% | 2.21M | $40.67B |
| 6 | BIIB | Biogen Inc. | 225.71 | +3.33% | 815.01K | $33.35B |
| 7 | BNTX | BioNTech SE ADR | 96.96 | +5.32% | 1.32M | $24.36B |
| 8 | EXEL | Exelixis Inc. | 59.86 | +1.42% | 2.67M | $14.83B |
| 9 | NBIX | Neurocrine Biosciences Inc. | 142.44 | +0.84% | 1.02M | $14.48B |
| 10 | HALO | Halozyme Therapeutics Inc. | 110.42 | +0.53% | 1.85M | $12.53B |
| 11 | TECH | Bio-Techne Corp | 72.46 | +0.01% | 2.23M | $11.36B |
| 12 | PCVX | Vaxcyte Inc. | 71.38 | +9.79% | 4.38M | $11.15B |
| 13 | IBRX | ImmunityBio Inc. | 10.51 | +6.05% | 18.66M | $11.14B |
| 14 | RGEN | Repligen Corporation | 173.88 | +6.13% | 1.34M | $11.04B |
| 15 | TWST | Twist Bioscience Corporation | 159.78 | +5.08% | 3.54M | $10.59B |
| 16 | KRYS | Krystal Biotech Inc. | 331.61 | +1.32% | 196.96K | $9.82B |
| 17 | QGEN | Qiagen N.V. | 45.38 | +1.91% | 1.26M | $9.37B |
| 18 | KYMR | Kymera Therapeutics Inc. | 112.40 | +2.84% | 1.31M | $9.25B |
| 19 | IOVA | Iovance Biotherapeutics Inc. | 14.62 | +9.84% | 16.99M | $6.62B |
| 20 | IMVT | Immunovant Inc. | 30.47 | +0.69% | 1.49M | $6.29B |
| 21 | KOD | Kodiak Sciences Inc | 99.87 | +5.95% | 1.74M | $6.28B |
| 22 | CGON | CG Oncology Inc. | 63.82 | +0.89% | 516.54K | $5.66B |
| 23 | CRSP | CRISPR Therapeutics AG | 53.39 | +5.85% | 1.47M | $5.16B |
| 24 | SRRK | Scholar Rock Holding Corporation | 42.19 | -0.02% | 1.26M | $5.14B |
| 25 | ADPT | Adaptive Biotechnologies Corporation | 26.49 | +1.53% | 1.53M | $4.23B |
| 26 | RLAY | Relay Therapeutics Inc. | 17.88 | +2.70% | 1.76M | $3.92B |
| 27 | TARS | Tarsus Pharmaceuticals Inc. | 73.16 | +1.30% | 481.75K | $3.42B |
| 28 | DNLI | Denali Therapeutics Inc. | 19.45 | +4.18% | 1.34M | $3.11B |
| 29 | BEAM | Beam Therapeutics Inc. | 25.70 | +4.47% | 1.80M | $2.65B |
| 30 | RXRX | Recursion Pharmaceuticals Inc. Class A | 4.36 | +10.38% | 35.50M | $2.34B |
| 31 | ADMA | ADMA Biologics Inc | 10.36 | +0.29% | 2.83M | $2.32B |
| 32 | BCRX | BioCryst Pharmaceuticals Inc. | 8.55 | +3.14% | 2.31M | $2.18B |
| 33 | NVAX | Novavax Inc. | 12.75 | +15.80% | 19.03M | $2.10B |
| 34 | ALVO | Alvotech | 5.78 | +1.94% | 707.14K | $2.06B |
| 35 | VCEL | Vericel Corporation | 40.10 | +0.12% | 506.88K | $2.05B |
| 36 | VIR | Vir Biotechnology Inc. | 11.70 | +5.22% | 1.97M | $1.98B |
| 37 | MESO | Mesoblast Limited ADR | 14.29 | +3.93% | 178.17K | $1.86B |
| 38 | IMCR | Immunocore Holdings plc ADR | 29.39 | +1.03% | 452.84K | $1.51B |
| 39 | MAZE | Maze Therapeutics Inc. | 27.11 | +4.75% | 670.92K | $1.51B |
| 40 | COAG | Hemab Therapeutics Holdings Inc. | 31.62 | +2.36% | 619.09K | $1.48B |
| 41 | TSHA | Taysha Gene Therapies Inc. | 4.49 | +1.35% | 5.38M | $1.46B |
| 42 | INBX | Inhibrx Biosciences Inc. | 95.01 | +2.43% | 86.82K | $1.40B |
| 43 | REPL | Replimune Group Inc. | 13.42 | +2.91% | 2.02M | $1.26B |
| 44 | VOR | Vor Biopharma Inc. | 19.90 | +4.03% | 1.10M | $1.18B |
| 45 | IMTX | Immatics N.V. | 7.43 | +0.81% | 1.37M | $1.13B |
| 46 | MGTX | MeiraGTx Holdings plc | 10.69 | +1.81% | 523.43K | $1.03B |
| 47 | CGEM | Cullinan Therapeutics Inc. | 15.53 | +0.45% | 567.53K | $954.44M |
| 48 | ODTX | Odyssey Therapeutics Inc. | 19.00 | +4.86% | 325.59K | $913.11M |
| 49 | GLUE | Monte Rosa Therapeutics Inc. | 10.30 | -0.19% | 1.20M | $878.73M |
| 50 | DNA | Ginkgo Bioworks Holdings Inc. Class A | 13.00 | +14.64% | 4.51M | $875.42M |
Frequently asked questions
- How many biotechnology: biological products (no diagnostic substances) stocks are there?
- MetaCap tracks 133 US-listed stocks in the Biotechnology: Biological Products (No Diagnostic Substances) industry, with a combined market value of about $883.84B.
- What is the largest biotechnology: biological products (no diagnostic substances) company?
- Amgen (AMGN) is the largest biotechnology: biological products (no diagnostic substances) stock by market capitalization, at about $224.29B.
- What sector is the biotechnology: biological products (no diagnostic substances) industry in?
- The Biotechnology: Biological Products (No Diagnostic Substances) industry belongs to the Health Care sector. Sectors are broad groupings of related industries; industries group companies with very similar products or business models.
- How are biotechnology: biological products (no diagnostic substances) stocks doing today?
- As of October 11, 2026, the Biotechnology: Biological Products (No Diagnostic Substances) industry is up 3.71% on a market-cap-weighted basis.
Explore more
Prices as of Oct 11, 7:10 PM EDT. Market data is delayed at least 15 minutes and provided for informational purposes only. Not investment advice. Full disclaimer